Background: Acute pancreatitis (AP) is an acute inflammatory disorder
of the pancreas. The destruction of pancreatic parenchyma induces a
systemic activation of coagulation, kinin, complement and fibrinolytic
cascades with liberation of cytokines and reactive oxygen metabolites.
Peroxisome proliferator—activated receptors (PPARs) play key roles in the
processes of fat metabolism, adipocyte differentiation, tumorigenesis,
inflammation and variety of immune processes. Telmisartan is the only
angiotensin receptor blocker (ARB) that may modulate PPARy activation at
physiologic plasma concentrations. Telmisartan may reduce markers of
inflammation, such as interleukin-6 and C-reactive protein, oxidative stress
and improves markers of vascular function.
The aim of the current article was to investigate the possible antiinflammatory,
antioxidant effects, and peroxisome proliferator-activated
receptor-y (PPARy) properties of the angiotensin type I receptor blocker
telmisartan in experimentally induced acute pancreatitis.
Materials and Methods:Fifty male albino rats were divided randomly into
5 groups; control normal group and 4 acute pancreatic groups group (n=40).
Acute pancreatitis were induced by i.p. injection of 20% L-arginine
hydrochloride in saline (2x250 mg/100 g at I h interval) and subdivided
equally into acute pancreatic group (no treatment); AP treatedt with Tel or
Ros alone or their combination groups. Serum amylase and lipase activity
were determined. Also TNF-a, IL-6, MDA and CAT were estimated in
addition to histopathological examination.
Results: Ros alone or in combination with Tel induced significant
attenuation of serum amylase and lipase activity. Also TNF-a, IL-6, MDA
and CAT were improved. While Tel induced insignificant improvement of
previous parameters
Conclusion: Use of rosiglitazone associated with a reduced risk of AP by
improving inflammatory status and oxidative stress reflecting the important
role of PPAR-y in AP. Furthermore, telmisartan does not ameliorate acute
pancreatic inflammation. Both agents have affinity for PPAR-y, telmisartan
binds to the receptor in a different manner, resulting in distinct
pharmacological actions. |
